|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3750 AUD | 0.00% |
|
-6.25% | -42.31% |
| 06-26 | Recce Pharmaceuticals to Raise AU$4 million via Share Placement; Shares Down 17% | MT |
| 06-24 | Recce Pharmaceuticals Requests Trading Halt Ahead of Equity Raise | MT |
| Market Cap | 112M 77.81M 67.99M 62.44M 58.23M 110M 7.41B 752M 291M 3.63B 292M 286M 12.52B | P/E 2026 * |
-5.28x | P/E 2027 * | -3.46x |
|---|---|---|---|---|---|
| Enterprise Value | 120M 83.46M 72.93M 66.97M 62.45M 118M 7.95B 806M 312M 3.9B 313M 307M 13.43B | EV / Sales 2026 * |
15.7x | EV / Sales 2027 * | 16.5x |
| Free-Float |
57.05% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 week | -6.25% | ||
| Current month | -7.41% | ||
| 1 month | -27.88% | ||
| 3 months | -17.58% | ||
| 6 months | -44.85% | ||
| Current year | -42.31% |
| 1 week | 0.37 |  | 0.44 |
| 1 month | 0.37 | | 0.52 |
| Current year | 0.37 | | 0.73 |
| 1 year | 0.29 | | 0.73 |
| 3 years | 0.28 | | 0.78 |
| 5 years | 0.28 | | 1.38 |
| 10 years | 0.13 | | 1.88 |
| Manager | Title | Age | Since |
|---|---|---|---|
James Graham
CEO | Chief Executive Officer | - | 27/08/2020 |
Justin Reynolds
DFI | Director of Finance/CFO | - | - |
Michele Dilizia
CTO | Chief Tech/Sci/R&D Officer | - | 29/09/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
Michele Dilizia
BRD | Director/Board Member | - | 30/09/2012 |
James Graham
BRD | Director/Board Member | - | 30/04/2012 |
| Director/Board Member | - | 31/08/2022 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 02-23 | Expiration | Chief Executive Officer | 2,250,000 | 0.7781% | ||
| 13/10/25 | Expiration | Chief Executive Officer | 745,962 | 0.3217% | ||
| 20/11/24 | Buy | Chief Executive Officer | 3,000,000 | 1.2938% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | -6.25% | +25.00% | -40.00% | 77.81M | |
| +1.86% | +7.65% | +55.77% | +158.84% | 1,082B | |
| +3.57% | +7.42% | +69.09% | +58.92% | 633B | |
| +3.99% | +7.37% | +36.87% | +93.77% | 461B | |
| +2.86% | -1.94% | +26.41% | +20.22% | 339B | |
| -0.75% | +0.94% | +41.63% | +39.31% | 301B | |
| -0.42% | +1.11% | +31.90% | +44.21% | 292B | |
| -1.73% | +2.70% | -25.43% | -39.67% | 225B | |
| +3.55% | +6.05% | +26.04% | +68.52% | 202B | |
| +4.21% | +6.00% | +17.72% | +70.33% | 163B | |
| Average | +1.23% | +4.07% | +30.50% | +47.44% | 369.98B | |
| Weighted average by Cap. | +1.28% | +5.21% | +41.73% | +81.22% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.68M 5.32M 4.65M 4.27M 3.98M 7.55M 507M 51.41M 19.92M 248M 19.98M 19.54M 856M | 8.86M 6.14M 5.37M 4.93M 4.6M 8.71M 585M 59.35M 23M 287M 23.07M 22.57M 988M |
| Net income | -20.45M -14.17M -12.39M -11.37M -10.61M -20.11M -1.35B -137M -53.07M -662M -53.22M -52.07M -2.28B | -30.9M -21.42M -18.72M -17.19M -16.03M -30.39M -2.04B -207M -80.21M -1B -80.43M -78.69M -3.45B |
| Net Debt | 8.15M 5.65M 4.94M 4.53M 4.23M 8.01M 538M 54.58M 21.15M 264M 21.21M 20.75M 909M | 33.53M 23.24M 20.31M 18.65M 17.39M 32.97M 2.21B 225M 87.03M 1.09B 87.28M 85.38M 3.74B |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/07/26 | A$0.3750 | 0.00% | 222,492 |
| 02/07/26 | A$0.3750 | -1.32% | 680,782 |
| 01/07/26 | A$0.3800 | -6.17% | 808,927 |
| 30/06/26 | A$0.4050 | -3.57% | 1,368,676 |
| 29/06/26 | A$0.4200 | +5.00% | 368,041 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- RCE Stock
Select your edition
All financial news and data tailored to specific country editions
